文献速递神经肿瘤

利用传统与先进机器学习整合肿瘤学数据并预测结局

Leveraging traditional and advanced machine learning for comprehensive oncology data integration and outcome prediction.
PubMed 文献 · J Neurooncol · 2026-10-12

该叙述性综述检索PubMed和Embase,评估肿瘤学数据库、机器学习模型及多模态数据整合在神经肿瘤中的应用。传统机器学习已用于生存预测、复发分类等,先进架构扩展了非结构化多模态数据分析能力;多模态AI常优于单模态,但临床实施受限于数据异质性、外部验证不足和可解释性问题。

要点

  • 传统机器学习已用于神经肿瘤的生存预测、复发分类和治疗反应评估。
  • 多模态AI整合影像、分子、病理和临床数据常优于单模态模型。
  • 临床实施受限于数据异质性、外部验证不足和可解释性担忧。

核心结论

  • AI与机器学习能整合复杂神经肿瘤数据,更贴近真实临床决策,但多数模型仍处于研究阶段。
  • 多模态AI框架可能最终改善预后评估、治疗分层和精准神经肿瘤诊疗。

研究设计与样本

  • 叙述性综述,检索PubMed和Embase,优先纳入2020至2026年发表的相关研究,并补充重要里程碑研究。

主要发现

  • 传统机器学习方法包括回归模型、随机森林、支持向量机和梯度提升算法,已用于生存预测、复发分类、治疗反应估计和分子生物标志物预测。
  • 先进架构包括自然语言处理、大语言模型、视觉变换器、几何深度学习和图神经网络,扩展了对放射报告、组织病理切片、MRI容积、分子数据集和电子健康记录等非结构化及多模态数据的分析能力。
  • 整合影像、分子、组织病理、临床和社会经济数据的多模态AI系统,常较单模态模型表现出更好的预测性能。

临床怎么用

  • 多模态AI框架有望辅助神经肿瘤的预后评估、治疗分层和精准诊疗决策。
  • 临床落地前需关注数据异质性、外部验证和模型可解释性,并积累代表性数据。

局限性

  • 数据集异质性、外部验证有限、可解释性担忧以及患者群体代表性不一致,限制广泛临床实施。
  • 多数当前模型仍处于研究阶段。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Outcome prediction in neuro-oncology remains challenging due to heterogeneity in tumor biology, imaging characteristics, treatment response, and patient-specific clinical factors. Although molecular databases have advanced understanding of brain tumor biology, many datasets lack broader data necessary for generalizable predictive modeling. Artificial intelligence (AI) and machine learning (ML) are increasingly being explored to integrate these heterogeneous data sources and support precision neuro-oncology. METHODS: A narrative review was performed using PubMed and Embase to identify studies evaluating oncology databases, ML models, multimodal data integration, and AI applications relevant to neuro-oncology. Studies published between 2020 and 2026 were preferentially reviewed, with additional landmark studies included when relevant. RESULTS: Traditional ML approaches including regression-based models, random forests, support vector machines, and gradient boosting algorithms have been applied to survival prediction, recurrence classification, treatment response estimation, and molecular biomarker prediction using clinical, imaging, molecular, and population-level datasets. More advanced architectures including natural language processing, large language models, vision transformers, geometric deep learning, and graph neural networks have expanded the ability to analyze unstructured and multimodal data sources including radiology reports, histopathology slides, MRI volumes, molecular datasets, and electronic health records. Multimodal AI systems integrating imaging, molecular, histopathologic, clinical, and socioeconomic data frequently demonstrated improved predictive performance compared with single-modality models. However, widespread clinical implementation remains limited by dataset heterogeneity, limited external validation, interpretability concerns, and inconsistent representation across patient populations. CONCLUSIONS: AI and ML approaches are increasingly capable of integrating complex neuro-oncology datasets in ways that more closely reflect real-world clinical decision-making. Although most current models remain investigational, multimodal AI frameworks may ultimately improve prognostic assessment, treatment stratification, and precision neuro-oncology care. Continued progress will require larger representative datasets, improved data harmonization, external validation, and clinically interpretable models.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Hey G, Del Sesto M, Still M, et al. Leveraging traditional and advanced machine learning for comprehensive oncology data integration and outcome prediction. J Neurooncol. 2026. PMID: 42862479. doi:10.1007/s11060-026-05774-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。